Search

GC-373

GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031,A219036]. … It is an inhibitor of M^pro (otherwise known as 3CL^pro), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036

Mycobacterium w. Vaccine

The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. … As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis.

VA-MENGOC-BC®

VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. … As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C.

CIGB 2020 Vaccine

As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.

BacTRL-spike

As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids.

Boldo leaf extract

Boldo leaf extract allergenic extract is used in allergenic testing.

Potassium aspartate

Covax-19™

Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).

Gam-COVID-Vac

-2 spike glycoprotein. … The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac Lyo).

SARS-CoV-2 Sclamp

As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). … Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.